Biomimetic human tissue models



Human cells and tissues

Human tissue- and disease models in OrganoPlates are more predictive

We develop our organs-on-chips models using a range of cell types, human whenever possible. Ideally we select primary cells or cells that have important biological features of primary cells. For example, we work with proximal tubule cells that express the important transporters, such as OATs and MATEs. We also have extensive programs using iPS cells, such as neurons and endothelial cells. Neurons in OrganoPlates® are excitable and express all relevant mature neuronal markers. In addition, LGR5+ organoids can be easily implemented in OrganoPlates®.

By selecting the best available human cell models, the most suitable extracellular matrix gels and the right culture media, we develop 3D cell culture models that represent human tissues as good as possible for the purpose. All under continuous perfusion, with co-culture in the perfectly controlled 3D environment of OrganoPlates®. Thus creating models that are better representations of healthy and diseased states as compared to standard cell lines in 2D or animal models.

Pharmacological compounds and chemicals

Drug-induced leakage of kidney proximal tubules

We challenge our models with drug compounds in order to validate their use as true biomimetic models for drug development. For example, our kidney tox models respond to hard-to-detect nephrotoxic compounds. Our neuronal models show the effects of seizure-inducing compounds and our vascular models respond to angiogenic and inflammatory stimuli. Our aim is to develop truly predictive tissue models in OrganoPlates®, based on the industry-standard 384-well plate for full compatibility with liquid handling- and readout equipment.

Equally important, we only use low-compound-absorbing materials in OrganoPlates®, to guarantee complete control of drug concentrations in your assays. For example, we do not use PDMS (Polydimethylsiloxane) in our products, which is notorious for absorbing hydrophobic pharmaceutical compounds.